Amazon GLP-1 treatment
Source: Amazon Inc.
Amazon is moving deeper into the burgeoning weight loss market, announcing a new program on Tuesday aimed at simplifying access to the popular GLP-1 therapy.
The company announced that its primary care division, Amazon One Medical, will launch a GLP-1 management program to integrate obesity treatment into routine care. The service combines virtual and in-person visits, prescription management, and pharmacy fulfillment, positioning weight management as a long-term chronic disease rather than a one-time prescription.
Tanvi Patel, vice president and general manager of Amazon Pharmacy, said in the company’s press release: “Providing customers with fast and convenient access to medicines and clear, transparent pricing is essential as Amazon Pharmacy transforms the pharmacy experience.”
“Expanding access to the latest GLP-1 treatments with upfront, transparent pricing will make it easier for customers to receive the treatments prescribed by their healthcare providers and keep them on track by ensuring those treatments are delivered directly to patients,” Patel said.
Through Amazon Pharmacy, patients will have access to medications such as: novo nordisk Wegovy and new oral GLP-1 options. According to Amazon, insurance prices start at $25 per month. For cash-paying patients, monthly prices for oral medications start at $149.
Wegovy shots and Eli Lilly’s Amazon says Zepbound starts at $299 per month when paid without insurance.
These prices are roughly in line with most of the current market.
But Amazon’s advantage lies in same-day delivery and convenience as it looks to leverage its logistics network and consumer reach into other parts of the health care system.
The company also announced it will now offer on-demand prescription renewals. Prices start at $29 for message consultation and $49 for video care. Amazon plans to expand its same-day medical delivery service to 4,500 cities by the end of 2026.
Shares of several companies tied to the obesity drug boom fell following Amazon’s Tuesday announcement. his and her health, Viking Therapeutics, amgen and septerna.
